## **CLAIMS**

## We claim:

5

10

15

20

30

- 1. A method of screening drug candidates comprising:
  - providing a cell that expresses an expression profile gene encoding CBK8 or fragment thereof;
  - b) adding a drug candidate to said cell; and
  - c) determining the effect of said drug candidate on the expression of said expression profile gene.
- 2. A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
- 3. A method of screening for a bioactive agent capable of binding to CBK8 or a fragment thereof, said method comprising:
  - a) combining sald CBK8 or a fragment thereof and a candidate bioactive agent; and
  - b) determining the binding of said candidate agent to said CBK8 or a fragment thereof.
- 4. A method for screening for a bioactive agent capable of modulating the activity of CBK8, said method comprising:
  - a) combining CBK and a candidate bioactive agent; and
  - b) determining the effect of said candidate agent on the bioactivity of CBK8.
- 5. A method of evaluating the effect of a candidate colorectal cancer drug comprising:
  - a) administering said drug to a patient;
  - b) removing a cell sample from said patient; and
  - c) determining the expression of a gene encoding CBK8 or fragment thereof.
- 6. A method according to claim 5 further comprising comparing said expression profile to an expression profile of a healthy individual.
  - 7. A method of diagnosing colorectal cancel comprising:
    - a) determining the expression of a gene encoding CBK8 or a fragment thereof in a first colon tissue of a first individual; and
    - b) comparing said expression of said gene(s) from a second normal colon tissue from said first individual or a second unaffected individual;

wherein a difference in said expression indicates that the first individual has colorectal cancer.


5

10

15

20

- 8. An antibody which specifically binds to CBK8 or a fragment thereof.
- 9. The antibody of Claim 8, wherein said antibody is a monoclonal antibody.
- 10. The antibody of Claim 8, wherein said antibody is a humanized antibody.
- 11. The antibody of Claim 8, wherein said antibody is an antibody fragment.
- 12. The antibody of Claim 8, wherein said antibody modulates the bioactivity of CBK8.
- 13. The antibody of Claim 12, wherein said antibody is capable of inhibiting the bioactivity or neutralizing the effect of CBK8.
- 14. A method for screening for a bioactive agent capable of interfering with the binding of CBK8 or a fragment thereof and an antibody which binds to CBK8 or fragment thereof, said method comprising:
  - a) combining CBX8 or fragment thereof, a candidate bioactive agent and an antibody which binds to CBK8 or fragment thereof; and
  - b) determining the binding of CBK8 or fragment thereof and said antibody.
- 15. A method according to Claim 14, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of CBK8.
- 16. A method for inhibiting the activity of CBK8, said method comprising binding an inhibitor to CBK8.
- 17. A method according to claim 16 wherein said inhibitor is an antibody.
- 18. A method of neutralizing the effect of CBK8 or a fragment thereof, comprising contacting an agent specific for said CBK8 or fragment thereof with said CBK8 or fragment thereof in an amount sufficient to effect neutralization.
  - 19. A method of treating colorectal cancel comprising administering to a patient an inhibitor of CBK8.
  - 20. A method according to claim 19 wherein said inhibitor is an antibody.



- 22. The method of Claim 21, wherein said therapeutic moiety is a cytotoxic agent.
- 5 23. The method of Claim 21, wherein said therapeutic moiety is a radioisotope.
  - 24. A method of treating colorectal cancer comprising administering to an individual having said colorectal cancer an antibody to CBK8 or fragment thereof conjugated to a therapeutic moiety.
  - 25. The method of Claim 24, wherein said therapeutic moiety is a cytotoxic agent.
  - 26 The method of Claim 24, wherein said therapeutic moiety is a radioisotope.
  - 27. A method for inhibiting colorectal cancer in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of figure 1.
  - 28. A biochip comprising one or more nucleic acid segments encoding CBK8 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.
  - 29. A method of eliciting an ininhund response in an individual, said method comprising administering to said individual a composition comprising CBK8 or a fragment thereof.
  - A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding CBK8 or a fragment thereof.
  - 31. A method for determining the prognosis of an individual with colorectal cancer comprising determining the level of CBK8 in a sample, wherein a high level of CBK8 indicates a poor prognosis.

10

15

20